NeuroNascent, Inc.
Neuronascent is a biotechnology company focused on generating new neurons and reversing neurological disorders. It develops small-molecule therapeutics aimed at neurogenesis and neuron regeneration, with ongoing R&D programs targeting diseases such as Alzheimer’s and Parkinson’s. The company is led by a team of experienced scientists and industry professionals dedicated to advancing neuroregenerative therapies.
Industries
Nr. of Employees
small (1-50)
NeuroNascent, Inc.
Clarksville, Maryland, United States, North America
Products
Small-molecule neuroregenerative clinical candidate (early-phase)
Orally administered small-molecule therapeutic candidate developed to stimulate neurogenesis and reverse cognitive deficits; progressed to Phase 1a safety testing in older adults.
Small-molecule neuroregenerative preclinical candidate with orphan/rare pediatric designations
Preclinical-stage therapeutic candidate targeting developmental and pediatric neurodevelopmental disorders, with regulatory orphan and rare pediatric drug designations.
Small-molecule neuroregenerative clinical candidate (early-phase)
Orally administered small-molecule therapeutic candidate developed to stimulate neurogenesis and reverse cognitive deficits; progressed to Phase 1a safety testing in older adults.
Small-molecule neuroregenerative preclinical candidate with orphan/rare pediatric designations
Preclinical-stage therapeutic candidate targeting developmental and pediatric neurodevelopmental disorders, with regulatory orphan and rare pediatric drug designations.
Services
Collaborative translational research and partnerships
Partnerships with academic and research institutions for translational studies, including studies in companion animals to model age-related cognitive decline.
Collaborative translational research and partnerships
Partnerships with academic and research institutions for translational studies, including studies in companion animals to model age-related cognitive decline.
Expertise Areas
- Neuroregenerative therapeutics
- Small-molecule CNS drug discovery
- Preclinical model development
- Clinical trial management (early-phase)
Key Technologies
- Small-molecule therapeutics
- Allosteric kinase modulation
- Neurogenesis-stimulating pharmacology
- Progressive MPTP Parkinson's disease model